Security Snapshot

InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) Institutional Ownership

CUSIP: 457637601

13F Institutional Holders and Ownership History from Q3 2022 to Q1 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Shares outstanding
804,525
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • INM - InMed Pharmaceuticals Inc. - Common Shares, no par value is tracked under CUSIP 457637601.
  • Latest finished 13F holder period is not available.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 0 to 0 between Q4 2024 and Q1 2025.
  • SEC-reported value moved from $0 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

457637601

Latest holder period

n/a

13F holders

13D/G owners

1

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
1
Security
INM
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
YA II PN, Ltd. 10% $14,885 80,372 YA II PN, Ltd. 13 Dec 2024

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
11
Latest
n/a
Rows shown
1-11 of 11
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q1 0 $0 -$5 0
2024 Q4 0 $0 -$265,983 0
2024 Q3 1,141,865 $265,983 +$152,049 $0.24 12
2024 Q2 440,244 $116,623 -$95,797 $0.27 10
2024 Q1 685,852 $249,191 -$42,696 $0.36 14
2023 Q4 804,163 $334,349 +$315,907 $0.42 13
2023 Q3 26,865 $18,551 +$7,235 $0.69 8
2023 Q2 15,650 $14,412 -$91,568 $0.92 7
2023 Q1 100,918 $109,292 -$123,996 $1.08 12
2022 Q4 115,828 $234,169 -$203,650 $2.00 11
2022 Q3 132,993 $876,125 +$876,125 $6.58 8
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .